Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities by Sonneveld, E. et al.
Comparison of In Vitro and In Vivo Screening Models for Androgenic
and Estrogenic Activities
Edwin Sonneveld,*,1 Jacoba A. C. Riteco,* Hendrina J. Jansen,* Bart Pieterse,* Abraham Brouwer,*,†
Willem G. Schoonen,‡ and Bart van der Burg*
*BioDetection Systems B.V., Amsterdam, The Netherlands; †Institute for Environmental Studies, Vrije Universiteit Amsterdam, Amsterdam,
The Netherlands; and ‡Department of Pharmacology, NV Organon, Oss, The Netherlands
Received August 25, 2005; accepted September 27, 2005
Identification of nuclear receptor–mediated endocrine activities
is important in a variety of fields, ranging from pharmacological
and clinical screening, to food and feed safety, toxicological
monitoring, and risk assessment. Traditionally animal studies
such as the Hershberger and Allen-Doisy tests are used for the
assessment of androgenic and estrogenic potencies, respectively.
To allow fast analysis of the activities of new chemicals, food
additives, and pharmaceutical compounds, high-throughput
screening strategies have been developed. Here, a panel of mainly
steroidal compounds, screened in different in vitro assays, was
compared with two human U2-OS cell line–based CALUX
(Chemically Activated LUciferase eXpression) reporter gene
assays for androgens (AR CALUX) and estrogens (ERa CALUX).
Correlations found between the data of these two CALUX
reporter gene assays and data obtained with other in vitro
screening assays measuring receptor binding or reporter gene
activation (CHO cell line–based) were good (correlation coeffi-
cients (r2) between 0.54 and 0.76; p < 0.0001). Good correlations
were also found between the in vitro and in vivo data (correlation
coefficient r2 = 0.46 for the AR CALUX vs. Hershberger assay and
r2 = 0.87 for the ERa CALUX vs. Allen-Doisy assay). The
variations in the results obtained with the reporter gene assays
(CALUX vs. CHO cell line based) were relatively small, showing
the robustness of these types of assays. Using hierarchical
clustering, bioactivity relationships between compounds but also
relationships between various bioassays were determined. The
in vitro assays were found to be good predictors of in vivo
androgenic or estrogenic activity of a range of compounds,
allowing prescreen and/or possible reduction of animal studies.
Key Words: androgen; estrogen; CALUX; bioassay; Hershberger;
Allen-Doisy.
Steroid hormones are essential for reproduction, stress
management, salt and glucose balances, as well as several
other physiological processes. Due to the relatively simple
chemical structure and lipophilic nature of steroids, their
regulatory pathways can easily be modified by pharmacolog-
ical, environmental, and/or dietary agents. Because of this,
steroids or steroid-mimicking compounds are applied in many
fields, making identification of the endocrine activity of these
compounds important. Analytical-chemical and immunologi-
cal methods are commonly used to detect steroids in food and
feed, clinical practice, environmental samples, or doping
control. These methods have the drawback that they only
quantify the compound of interest and are not able to determine
biological activity of unknown compounds or their metabolites,
this in contrast to biological assays.
Bioassays in rats, mice, or rabbits were developed a long
time ago to determine the endocrine activity of compounds.
Important examples are the assessment of vaginal smear types
to define estrogenicity (Allen and Doisy, 1923) and of the
prostate, seminal vesicle, and musculus levator ani (MLA)
growth to determine androgenic and anabolic activities
(Hershberger et al., 1953; van der Vies and de Visser, 1983).
The contribution of animal studies, however, is hampered,
particularly with respect to sensitivity, capacity, costs, the
desire to limit animal use, and speed. To allow fast analysis of
new chemicals, food additives, and pharmaceutical com-
pounds, high throughput screening assays have been devel-
oped. These assays are based on the mechanism of action of
compounds and are able to measure activation or inhibition of
specific cellular pathways. These mechanism-based assays, in
combination with rapid advance in automated screening
technologies and bioinformatics, create new possibilities to
limit animal studies. These in vitro detection systems are ideal
for first-line screening, while positive hits can be tested more
extensively using more specialized cell culture systems and
animal models.
The mechanism of action of steroid hormones is well
established, and opened opportunities for mechanism-based
assays. Steroid hormones like estrogens and androgens are
nuclear hormone receptor ligands that enter cells by diffusion
where they bind to their cognate steroid receptors. Five major
types of steroid receptors are known: those for estrogens, andro-
gens, progestagens, glucocorticoids, and mineralocorticoids
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(Mangelsdorf et al., 1995; McKenna and O’Malley, 2002), now
classified as members of the subfamily 3 within the nuclear
receptor family (Nuclear Receptors Nomenclature Committee,
1999). Upon ligand binding these receptors become activated,
and they will enter the nucleus and bind to recognition
sequences in promoter regions of target genes, the hormone
responsive elements. Depending on the presence of receptor-
interacting proteins, so-called cofactors including coactivators
as well as corepressors (Chang and McDonnell, 2005;
McDonnell and Norris, 2002), the DNA-bound receptor will
activate transcription of the target gene, leading to new protein
synthesis and an altered cellular functioning. Besides the
classical genomic-based action of steroid hormones involving
nuclear hormone receptors, rapid nongenomic mechanisms of
steroids might also occur via putative membrane-bound
receptors, at least for estrogen and progesterone signaling
(Luconi et al., 2004).
A whole range of so-called reporter gene assays have been
developed by us and by others for compounds interacting with
a range of steroid receptors, including the estrogen and
androgen receptor (Balaguer et al., 1999; de Gooyer et al.,
2003; Legler et al., 1999; Schoonen et al., 2000a,b; Sonneveld
et al., 2005; Terouanne et al., 2000). In these reporter gene
assays, DNA sequences containing specific hormone-responsive
elements are linked to the gene of an easily measurable protein
(the reporter gene; e.g., firefly luciferase). When stably in-
troduced in a cell line expressing the cognate receptor, or by
double transfection with a receptor of interest, a specific
reporter cell line is generated allowing large scale screening
of compounds. Similarly, simple receptor binding assays can be
used to exert such screenings. However, the latter cannot
distinguish between receptor interacting compounds that will
lead to (partial) transcriptional activation or (partial) transcrip-
tional inhibition of the receptor.
In this study we determined the suitability of two different
reporter gene assays, either U2-OS or CHO cell line based, and
two receptor binding assays using MCF-7 cells (Bergink et al.,
1983) as a prescreen for, or limitation of animal studies
(ECVAM working group on chemicals, 2002) in determining
androgenic and estrogenic activities of compounds. The in vitro
assays (AR/ER binding and AR/ERa reporter gene assays)
were found to be good predictors of AR/ER in vivo agonist
activity of a range of mainly steroidal compounds.
MATERIALS AND METHODS
Chemicals. Androstenedione, diethylstilbestrol (DES), dexamethasone
(DEX), 5a-dihydrotestosterone (DHT), 17a-estradiol, 17b-estradiol (E2),
estriol, estrone, 17a-ethinyl-estradiol (EE), flutamide, genistein, levonorgestrel
(LNG), 17a-methyl-testosterone (MT), mifepristone (RU486), norethynodrel
(NE), progesterone, tamoxifen citrate, testosterone (T), and testosterone
propionate (TP) were obtained from Sigma-Aldrich (Zwijndrecht, The
Netherlands). Methyltrienolone (R1881) was obtained from Perkin Elmer
(Perkin Elmer, Groningen, The Netherlands). Cyproterone acetate (CA),
medroxyprogesterone acetate (MPA), and 19-nor-testosterone (nandrolone)
were obtained from Steraloids Inc. (Newport, RI). All other used compounds
were supplied by the Department of Medicinal Chemistry of N.V. Organon (Oss,
The Netherlands). All chemicals were diluted in either ethanol or dimethylsulph-
oxide (DMSO, 99.9%, Acros, Geel, Belgium) and stored at 20C. Neomycin
(G418) was purchased from Life Technologies (Breda, The Netherlands).
Animals. SPF-bred immature male and young female HSD/Cpb:ORGA
rats were supplied by The Harlan Sprague-Dawley/Central Institute for the
Breeding of Laboratory Animals of the Dutch Organization for Applied
Scientific Research ((HSD-CPB), Zeist, The Netherlands). Rats were housed in
light-, humidity- and temperature-controlled rooms (14 h light–10 h dark; 21–
23C), and given tap water and pelleted food (RMH-B, Hope farms,
Linschoten, The Netherlands) ad libitum. Animal handling was in accordance
with the Dutch law on Animal Experimentation and the European Directive for
the Protection of Vertebrate Animals used for Experimental and other Scientific
Purposes (EU directive #86/606/CEE). The Committee for Experiments on
Animals of N.V. Organon approved the experiments.
Cell culture. Human MCF-7 cells were cultured in a 1:1 mixture of
Dulbecco’s modified Eagle’s medium and Ham’s F12 medium (DF, Gibco)
supplemented with 5% fetal calf serum (FCS). U2-OS-based AR and ERa
CALUX cells, stably expressing human AR and ERa and their corresponding
luciferase reporter genes (e.g., multimerized responsive elements for the
cognate receptor coupled to a minimal promoter element (the TATA box) and
luciferase) (Legler et al., 1999; Sonneveld et al., 2005) were cultured in DF
medium supplemented with 7.5% FCS and 200 lg/ml G418. Chinese Hamster
Ovary CHO-AR and CHO-ERa cells stably expressing human AR and ERa and
their corresponding luciferase reporter genes (e.g., the mouse mammary tumor
virus promoter (MMTV) for AR and the rat oxytocin promoter (RO) for ERa
coupled to the luciferase reporter gene), respectively, were cultured as
described earlier (Schoonen et al., 2000a,b).
Reporter gene assays. AR and ERa CALUX cells were plated in 96-well
plates (8000 cells/well) with phenol red-free DF medium supplemented with
5% dextran-coated charcoal-stripped FCS (DCC-FCS; van der Burg et al.,
1988) at a volume of 200 ll per well. Two days later, the medium was
refreshed, and cells were incubated with the compounds to be tested (dissolved
in ethanol or DMSO) in triplicate at a 1:1000 dilution. After 24 h the medium
was removed, and cells were lysed in 30 ll Triton-lysis buffer and measured for
luciferase activity using a luminometer (Lucy2; Anthos Labtec Instruments,
Wals, Austria) for 0.1 min/well. For transactivation studies using CHO-derived
reporter gene assays, stably transfected CHO-AR and CHO-ERa cells were
used as described previously (Schoonen et al., 2000a,b). Data sets for the CHO
reporter gene assays were collected between 1995 and 2003 at Organon.
Receptor binding assays. For hAR and hER displacement analysis, MCF-7
cells were used. The cells were cultured, harvested, and cytosolic preparations
were prepared as described previously (Schoonen et al., 1995). Prior to use,
cytosol equivalent to 1 g of cells was diluted with buffer at a ratio of 1:10 for
hER and 1:5 for hAR (w/v). Samples were counted in a Topcount microplate
scintillation counter (Perkin Elmer). The specific 50% competition level of
each compound was analyzed in the range of 0.121 up to 1000 nM with a two-
fold dilution range. The relative binding affinities (RBAs) of the compounds
were obtained by a three-point parallel line analysis (Finney, 1978) using three
subsequent concentrations in the range of 25, 50, and 75% of competition for
each individual compound in relation to the reference compound. The reference
compound DHT, as well as E2, was measured in the range of 0.97, 1.95, and
3.90 nM (Schoonen et al., 1998, 2000a,b). Specific binding was determined by
subtracting nonspecific from total binding. The mean RBA values of at least
two different independent tests were calculated for each compound. The overall
statistical deviation (SD) was within the 5% level. Data sets for the receptor
binding assays were collected between 1983 and 2000 at Organon.
In vivo studies. The assay for androgenic-anabolic activity of the
compounds in immature male orchidectomized rats was performed according
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to the Hershberger test (Hershberger et al., 1953), with minor modifications
(van der Vies and de Visser, 1983). Groups of six animals per compound dose
were treated subcutaneously (sc) twice a day for seven consecutive days. At the
end of the treatment period autopsy was performed, and the weights of the
ventral prostate, seminal vesicles, and levator ani muscle were recorded.
Testosterone was used as a reference for subcutaneous administration in a dose
of 160 lg/kg as the minimal active dose (MAD). The MAD was determined as
the dose at which the ventral prostate weight was 1.8 times higher than the
placebo value. In vivo activities were calculated relative to testosterone. Data
sets for the Hershberger assay were collected between 1970 and 2000 at
Organon. The estrogenic activity of the compounds in ovariectomized rats was
determined by scoring vaginal cornification (Allen-Doisy test) as described
earlier (Allen and Doisy, 1923; van der Vies and de Visser, 1983). Female adult
rats were ovariectomized and primed 3 weeks later with a single dose of 1 lg
estradiol (sc). One week later the reference compound estradiol and the
compounds to be tested were administered (sc) with three subsequent equal
doses: one dose in the afternoon of the first day, and the next two doses in the
morning and afternoon of the following day. Vaginal smears were taken at the
end of the third day, twice the fourth day, and again on the morning of the last
day (day 5). The smears were stained with Giemsa and evaluated (de Jongh and
Laqueur, 1938). For estradiol a total dosing of 0.5 lg/kg was used to obtain the
minimal active dose (MAD). Each total dose is divided equally over three
administrations. Test compounds are administered in total doses of 0.05 lg/rat
up to 1.0 mg/rat. The usual phases observed in the morning of the 4-day estrus
cycle are di-estrus (score a), pro-estrus (score e) or estrus (score g). A rat is
considered to give a positive score if at least one of the smears indicates a score
of e, intermediate f or g. In total six rats per compound dose were treated, and
a score of 1 or 2 positive animals out of six is called weakly active, while a score
of 3 up to 6 out of six animals is called active. The total dose (sc) at which 50%
of the animals showed one or more positive smears is given as the minimal
active dose (MAD). In vivo activities were calculated relative to E2. Data sets
for the Allen-Doisy assay were collected between 1970 and 2000 at Organon.
Statistical analysis. Luciferase activity per well was measured as relative
light units (RLUs). Fold induction was calculated by dividing the mean value of
light units from exposed and nonexposed (solvent control) wells. For CALUX
cells, luciferase induction as a percentage of maximal DHT (AR CALUX) or
E2 (ERa CALUX) activity was calculated by setting the highest fold induction
of DHT or E2 at 100%. Data are represented as mean values ± SEM from at
least three independent experiments with each experimental point performed in
triplicate. Dose-response curves were fitted using the sigmoidal fit y¼ (a0þ a1)/
(1 þ exp[(x  a2)/a3]) in GraphPad Prism (version 4.00 for Windows,
GraphPad Software, San Diego, CA), which determines the fitting coefficients
by an iterative process minimizing the c2 merit function (least squares
criterion). The EC50 values were calculated by determining the concentration
by which 50% of maximum activity was reached using the sigmoidal fit
equation. At least eight different concentrations covering the total S-curve were
included for each compound. The relative transactivation activity (RTA) of each
compound tested was calculated as the ratio of maximal luciferase reporter
gene induction values of each compound and the maximal luciferase reporter
gene induction value of reference compound of the specific assay. The
transactivation activity of the reference compounds DHT or E2 was arbitrarily
set at 100. The relative agonistic activities (RAA) for the CALUX reporter gene
assays were calculated by dividing the EC50 concentration of the reference
compound with the EC50 concentration of the compound of interest. Relative
agonistic activity studies with CHO reporter gene assays were carried out with
five concentrations of the standards DHT and E2 at 1.503 1011, 3.003 1011,
6.00 3 1011, 1.21 3 1010, and 2.42 3 1010 M and three subsequent
concentrations of the compound of interest in the range of 1 pM up to 100 nM.
The relative agonistic activities of the compounds were obtained by a 3-point
parallel line analysis (Finney, 1978) using three up-following concentrations in
the range of 25, 50, and 75% activation for each individual compound in
relation to the reference compound (Schoonen et al., 1998, 2000a,b). The mean
RAA values were calculated from at least two different independent tests.
The overall SD was within the 5% level. In the in vivo Allen-Doisy and
Hershberger tests, the mean scores per dose were calculated. The RAA values
for in vivo compound testing were calculated by dividing the MAD of the
standards testosterone (Hershberger assay) or E2 (Allen-Doisy assay) by the
MAD of the compound of interest. Correlation coefficients (r2) and their
correspondent p-values were calculated with GraphPad Prism (version 4.00 for
Windows, GraphPad Software, San Diego, CA). Cutoff values were 0.0001 for
Allen-Doisy comparison, and 0.001 for reporter gene, receptor binding, and
Hershberger comparisons. Two-dimensional hierarchical clustering on the base
10 logarithm of the RAA data was performed using the correlation option
within the clustergram function from the bioinformatics toolbox in Matlab (The
Mathworks, the Netherlands).
RESULTS
Comparison of Different In Vitro Reporter Gene Assays for
Determination of Androgenic and Estrogenic Activities
The results obtained in two different laboratories were
compared by using a panel of mainly steroidal chemicals with
in vitro reporter gene assays for androgen and estrogen
receptors. The AR and ERa CALUX cell lines as well as the
CHO cell lines are efficient tools to screen for agonistic and
antagonistic effects of compounds toward the androgen re-
ceptor and estrogen receptor alpha, respectively (Schoonen
et al., 2000a,b; Sonneveld et al., 2005). AR and ERa CALUX
cells are human U2-OS cell line based with the same basal
characteristics as other CALUX reporter gene assays (ERb,
PR, and GR CALUX), being robust, easy maintainable, stable
and strongly responsive, and selective. The range in EC50
values measured with different ligands over time, including the
positive controls DHT (AR CALUX) and E2 (ERaCALUX), is
small, reflected by an inter-assay CV of 22% for the AR
CALUX and 25% for the ERa CALUX reporter gene assay
(Sonneveld et al., 2005).
Typical dose-response curves for several natural as well as
synthetic androgens and estrogens using AR and ERa CALUX
reporter gene assays, respectively, are shown in Figure 1. The
AR CALUX cell line showed high sensitivity toward all
androgens tested (Fig. 1A and Table 1), with the following
range of potencies (EC50 values): dihydrotestosterone (DHT;
110 pM), testosterone (T; 657 pM), and its 19-nor derivatives
nandrolone (19-nor-T; 301 pM), 19-nor-11-keto-T (2845 pM),
and 11-methylene-19-nor-T (98 pM). The selectivity of the AR
CALUX cells is high, since representative steroids for other
hormone receptors (E2 and EE for ER, progesterone for PR,
and dexamethasone for GR) showed no substantial agonistic
response, with relative agonistic activities below 0.001, except
for dexamethasone (0.003), which additionally has a relative
transcriptional activity (RTA) of 8% compared to DHT (see
Table 1; Sonneveld et al., 2005).
In line with the AR CALUX cell line, the ERa CALUX cell
line showed high sensitivity toward all estrogens tested, with
the following range of potencies (EC50 values): 11b-ethenyl-E2
(4 pM), E2 (16 pM), 3b-OH-5a-hydrogen-11b-ethenyl-NET
(86 pM), 19-nor-5a-NET (18000 pM), and norethisterone
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(NET; 189234 pM) (Fig. 1B and Table 2). As shown again,
minor steroid modifications greatly influence activity on the
ERa. Furthermore, the ERa CALUX cells showed high
selectivity toward estrogens, since representative steroids for
other hormone receptors (testosterone and DHT for AR,
progesterone for PR and dexamethasone for GR) showed no
substantial agonistic response (relative agonistic activities
below 0.0001) (Table 2).
The CHO-hAR and CHO-hERa cell lines used in this study
are members of a panel of CHO-derived steroid reporter cell
lines containing hERb, hPR, and hGR as well (Schoonen et al.,
2000a,b). The data generated at Organon originate from
a historical database, aimed at pharmaceutical applications
and dosages. For this reason, these data focused on relatively
high-potency compounds, allowing identification of com-
pounds that have EC50 values not lower than 0.001 times of
the reference compounds. Therefore, the relative potency
cutoff value for the correlation determination between AR or
ERa CALUX reporter gene assays and their corresponding
CHO reporter gene counterparts was set at 0.001, and relative
agonistic activities below this value were not included in the
correlation analysis. Furthermore, known AR antagonists
(flutamide, cyproterone acetate, RU486) and ERa antagonists
(tamoxifen, raloxifen, ICI 164.384) also were excluded in the
correlation since, although these compounds can bind to their
cognate receptor, they generally fail in transactivating, but can
be identified in an antagonistic setting (data not shown). Also
compounds for which no exact RAA was determined (indicated
as < or > in Tables 1 and 2) were excluded from the correlation.
Despite the different setups at the two laboratories, surpris-
ingly good correlations were found between data obtained with
the same compounds in the different reporter gene assays.
Figure 2 shows the correlation between data obtained between
the AR CALUX cells and CHO-AR cells (Fig, 2A: 47
compounds tested; r2 ¼ 0.75; p < 0.0001), and both ERa-
expressing cell lines (Fig. 2B: 36 compounds tested; r2 ¼ 0.74;
p < 0.0001). These correlation coefficients were very similar to
the correlation coefficients found in an unbiased approach
where no correlation exclusions were performed (comparison
between both AR reporter gene assays: n ¼ 60, r2 ¼ 0.76; ERa
reporter gene assays: n ¼ 61, r2 ¼ 0.78; data not shown). This
clearly shows that the data restrictions for correlation have no
influence on the correlation coefficients. Notable differences
between the AR CALUX and CHO-AR reporter gene assays
(more than 10 times difference between RAAs; see Table 1)
were: 17a-(2-propenyl)-19-nor-T, 11b-ethyl-NET, D15-NET
and T-17, 17#-(2, 2#-oxybisacetate) (all AR CALUX > CHO-
AR). Notable differences between the ERa CALUX and CHO-
ERa reporter gene assays (more than 10 times difference
between RAAs; see Table 2) were the natural estrogens estriol
and estrone (both ERa CALUX < CHO-ERa) and 17a-
iodovinyl-E2 (E) (ERa CALUX > CHO-ERa).
Because the CALUX datasets for both AR and ERa were
the most extensive, we focused on these datasets only and
compared these with the receptor binding assays and in vivo
assays.
Comparison of Reporter Gene Assays with Receptor
Binding Assays
The results of reporter gene assays were compared with
those of receptor binding assays. As for the comparison
between the different reporter gene assays, the relative potency
cutoff value for the correlation determination between RAAs
from AR or ERa CALUX reporter gene assays and their
corresponding relative binding activities (RBAs) derived from
AR and ER binding assays was set at 0.001. Figure 3 shows that
correlations found between the receptor binding and CALUX
reporter gene assays were excellent. When comparing AR
binding capacities of various androgens (43 compounds, see
Table 1) with transactivation potential of these compounds in
the AR CALUX reporter gene assay, a correlation coefficient of
FIG. 1. Dose response curves for different receptor activating compounds
in the AR and ERa CALUX reporter gene assays. AR and ERa CALUX cells
were plated in 96-well plates. AR CALUX cells (A) were treated with the
androgenic compounds DHT (n), testosterone (d), and its 19-nor derivatives
19-nor-11-keto-T (s), 11-methylene-19-nor-T (;), and 19-nor-T (h), and
ERa CALUX cells (B) were treated with the estrogenic compounds E2 (d),
11b-ethenyl-E2 (s), NET (:), 19-nor-5a-NET (n), and 3b-OH-5a-hydrogen-
11b-ethenyl-NET (h) for 24 h using DF medium containing 5% DCC-FCS.
Each point represents the mean of at least three independent experiments ±
SEM.
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TABLE 1
AR CALUX LogEC50 Values, Relative Transcriptional Activity (RTA), and Relative Agonistic Activity (RAA)
Compound
Modification AR CALUX
CHO-AR AR binding Hershberger
R3 R4–5 R6 R7 R11 R17 LogEC50(M) RTA (%) RAA 1 ¼ DHT RAA 1 ¼ DHT RBA 1 ¼ DHT RAA 1 ¼ T
Nandrolone derivatives
19-nor-T (Nandrolone) 9.5 92 0.486 0.530 0.474 0.080
6a-methyl-NET e i 8.9 50 0.139 0.021 0.083 nd
6a-methyl-19-nor-T e 9.6 127 0.464 1.256 0.895 >0.064
MENT ¼ 7a-methyl-19-nor-T e 10.1 121 1.983 2.630 1.405 1.280
7a-methyl-NET e i 9.7 78 0.912 0.206 0.291 0.500
7a-methyl-11b-methyl-NET e e i 9.4 69 0.397 0.166 0.253 0.008
7a-methyl-11-methylene-NET e f i 9.1 74 0.218 0.064 0.133 0.008
7a-methyl-11-ethylene-NET e g i 8.5 69 0.054 0.016 0.097 0.250
7a-methyl-17a-(2-propenyl)-19-nor-T e o 9.7 79 0.956 0.149 0.381 0.016
11a-OH-19-nor-T l 7.7 100 0.008 0.012 0.008 0.002
11b-OH-19-nor-T m 7.3 97 0.003 0.003 0.003 0.006
11b-methyl-19-nor-T e 9.6 120 0.734 1.200 0.620 <0.123
11-methylene-19-nor-T f 10.0 107 1.669 2.003 0.930 0.055
11b-ethyl-NET h i 8.0 48 0.017 0.003 0.020 0.032
11b-ethinyl-NET i i 8.5 64 0.051 0.020 0.046 0.051
11b-ethenyl-NET k i 7.1 36 0.002 0.004 0.021 0.005
11-keto-19-nor-T n 8.6 102 0.059 0.065 0.109 0.007
17a-methyl-19-nor-T e 9.9 87 1.301 0.815 0.380 >0.032
Norethisterone (NET) i 8.2 69 0.026 0.011 0.034 0.064
17a-(2-propenyl)-19-nor-T o 8.4 51 0.047 0.003 0.111 0.008
3-deoxy-11b-OH-19-nor-T a m 8.4 88 0.042 0.000 nd 0.032
3-deoxy-11-keto-17a-ethyl-19-nor-T a n h 8.0 44 0.017 0.000 nd 0.032
5a-hydrogen-7a-methyl-NET b e i 9.3 64 0.313 0.038 0.307 0.127
5a-hydrogen-11b-methyl-NET b e i 8.7 52 0.092 0.027 0.128 nd
5a-hydrogen-11b-ethyl-NET b h i 8.0 45 0.018 0.002 0.032 0.008
5a-hydrogen-11b-ethinyl-17a-
ethenyl-19-nor-T
b i k 8.7 53 0.092 0.040 0.025 nd
5a-hydrogen-11b-ethinyl-NET b i i 8.5 55 0.051 nd 0.070 0.016
5a-hydrogen-19-nor-T b 9.4 110 0.405 0.259 0.588 <0.008
5a-hydrogen-NET b i 8.5 149 0.056 0.008 0.051 0.032
5a-hydrogen-17a-(2-propenyl)-19-nor-T b o >6.0 23 0.007 0.001 0.025 0.008
D15-NET c i 8.3 57 0.036 0.001 0.025 0.043
7a-methyl-androst-5(10)-ene-19-nor-T d e 9.4 102 0.466 0.809 nd 0.160
Norethynodrel (NE) d i 8.2 48 0.027 0.006 0.007 0.008
Testosterone derivatives
T 9.2 94 0.146 0.168 0.171 1.000
T propionate p 9.1 81 0.200 nd nd >1.000
Testosterone derivatives (continued)
11-methylene-17b-propionate-T f p 8.7 86 0.080 0.017 nd 1.000
17a-methyl-T e 9.1 108 0.197 0.195 0.206 >1.000
T-17,17#-(2,2#-oxybisacetate) p 9.3 81 0.319 0.014 nd 0.032
7a-methyl-T e 8.5 87 0.051 0.455 0.250 nd
5a-hydrogen-T(DHT) b 9.9 100 1.000 1.000 1.000 >0.250
(14b,17a,20S)-20-OH-19-norpregna-4,
9-diene-3-one
9.7 90 0.975 0.530 0.400 0.127
(11b,14b,17a,20S)-11-ethenyl-20-OH-
19-norpregna-4,9-diene-3-one
9.4 82 0.453 0.345 0.405 0.127
Androst-4-ene-3,17-dione 8.4 82 0.057 nd 0.001 nd
R1881 9.9 69 1.063 0.976 0.595 nd
Flutamide >5.0 <5 0.000 <0.001 0.015 0.002
17b-mercapto-androst-4-en-3-one >6.0 41 0.000 <0.001 0.028 0.032
11b-ethenyl-19-nor-androstenedione k 8.3 71 0.036 0.026 nd 0.064
5a-Androstane-3a,17b-diol 7.7 66 0.009 0.003 nd 0.500
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r2 ¼ 0.74 ( p < 0.0001) was found (Fig. 3A). Some compounds
were found that showed relatively high binding activity
coupled to absent or low transactivation potential (Table 1).
These compounds were known full (flutamide) or partial
(cyproterone acetate; CA) AR antagonists and were therefore
not included in the correlation calculation. Also other com-
pounds showing absent or low AR transactivation activity
(relative potencies below 0.001 and therefore not included in
correlation) were found to bind the receptor with moderate
affinity: E2, 17a-estradiol, progesterone, norgestimate, allyles-
trenol, and RU 486 (Table 1). On the other hand, the relatively
high potency of the testosterone precursor androstenedione in
the AR CALUX cell line was obvious, while binding to the
androgen receptor was low, indicating the metabolic capacity
generating more active compounds in U2-OS (17b-HSD
activity).
In the comparison of ERa binding data with ERa trans-
activation data obtained for various estrogens (34 compounds,
see Table 2), a correlation coefficient of r2¼ 0.54 ( p < 0.0001)
was found (Fig. 3B). As for the AR, ERa antagonists
(tamoxifen, raloxifen and ICI 164.384) also were relatively
strong receptor binders while showing no transactivation
potential (Table 2) and were not included in the calculation.
Of the 34 included compounds, three compounds showed
over 10-fold differences in favor of ER binding: genistein
(153), 3b-OH-11b-ethyl-NET (163), 3a-OH-5a-hydrogen-
11b-ethyl-NET (123), and 3b-OH-5a-hydrogen-11b-ethyl-
NET (413), suggesting these may be weak transactivators
for ERa, as at higher dosages they still give full transactivation.
In addition, comparably good correlations were found using
CHO-derived reporter gene data and receptor binding data for
both AR (r2 ¼ 0.86; n ¼ 38; p < 0.0001) and ERa (r2 ¼ 0.69;
n ¼ 43; p < 0.0001) (data not shown).
Comparison of Reporter Gene Assay Data Sets with in Vivo
Assay Data Sets
To test whether reporter gene assays can be used as
prescreens or reduction of in vivo assays for hormonal activity,
we compared the AR and ERa CALUX data sets with in vivo
Hershberger and Allen-Doisy assays, respectively (Fig. 4;
Tables 1 and 2). The relative potency cutoff value for the
RAAs used in the correlation determination between the AR
CALUX reporter gene assay and the corresponding RAAs from
the Hershberger assay was set at 0.001, while the cutoff value
for the RAAs used in the comparison between the ERa
CALUX reporter gene assay and the Allen-Doisy assay was
set at 0.0001 due to a better dynamic determination range for
TABLE 1—Continued
Compound
Modification AR CALUX
CHO-AR AR binding Hershberger
R3 R4–5 R6 R7 R11 R17 LogEC50(M) RTA (%) RAA 1 ¼ DHT RAA 1 ¼ DHT RBA 1 ¼ DHT RAA 1 ¼ T
Progestagens
Progesterone >5.0 36 0.000 <0.001 0.019 0.064
Norgestimate 5.9 25 0.000 <0.002 0.027 nd
MPA 8.2 75 0.014 0.042 0.197 0.032
LNG 8.6 79 0.074 0.051 0.105 0.250
LNG acetate 9.1 59 0.222 0.061 nd 0.250
Cronolon >6.0 12 0.000 <0.002 0.010 nd
CA 5.4 50 0.001 <0.001 0.067 0.002
11-methylene-17a-azidomethyl-
18-methyl-19-nor-T
f 9.3 73 0.333 0.210 nd 0.500
11-methylene-17b-spiro-(Estr-4-ene-
17,2#(3#H)furan)-3-one
f 8.6 59 0.076 nd 0.053 0.032
RU 486 ¼ Mifepristone >5.0 <5 0.000 0.000 0.028 nd
Estrogens
EE i >5.0 <5 0.000 <0.001 0.003 nd
E2 5.5 93 0.000 <0.001 0.038 nd
17a-estradiol >5.0 <5 0.000 <0.001 0.034 >0.008
Allylestrenol >5.0 <5 0.000 <0.001 0.019 0.002
7a-methyl-17a-(2-propenyl)-estr-
5(10)-en-17b-ol
9.2 71 0.250 0.064 nd 0.032
Glucocorticoid
Dexamethasone 7.3 8 0.003 <0.001 0.001 <0.032
Note. LogEC50 values, Relative Transcriptional Activity (RTA), and Relative Agonistic Activity (RAA) of various compounds in the AR CALUX reporter
gene assay, and their corresponding RAA and Relative Binding Activity (RBA) in the CHO-AR reporter gene assay, AR binding assay, and Hershberger assay.
nd ¼ not determined. Abbreviations: a ¼ 3-deoxy; b ¼ 5a-hydrogen; c ¼ D15; d ¼ D5–10; e ¼ methyl; f ¼ methylene; g ¼ ethylene; h ¼ ethyl; i ¼ ethinyl; k ¼
ethenyl; l ¼ a-hydroxy; m ¼ b-hydroxy; n ¼ keto; o ¼ 2-propenyl; p ¼ propionate; R3 ¼ 3-position; R4–5 ¼ 4–5-position; R6 ¼ 6a-position; R7 ¼ 7a-position;
R11 ¼ 11-position; R17 ¼ 17-position.
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TABLE 2
ERa CALUX LogEC50 Values, Relative Transcriptional Activity (RTA), and Relative Agonistic Activity (RAA)
Compound
Modification ERa CALUX
CHO-ERa ER binding Allen-Doisy
R3 R4–5 R6 R7 R11 R17 LogEC50 (M) RTA (%) RAA 1 ¼ E2 RAA 1 ¼ E2 RBA 1 ¼ E2 RAA 1 ¼ E2
Estradiol derivatives
E2 (17b-Estradiol) 10.8 100 1.0000 1.0000 1.0000 1.0000
Estriol 9.9 100 0.0355 0.3020 0.0650 0.0156
Estrone 9.0 119 0.0159 0.2210 0.0670 0.1250
11-methylene-E2 f 10.9 91 0.9947 0.9150 1.6000 1.3300
11b-methyl-E2 e 11.2 109 2.7473 0.7050 0.9020 nd
11b-ethenyl-E2 k 11.4 84 3.1584 1.0450 1.3200 2.0000
11b-ethinyl-E2 i 11.1 85 1.6830 0.6950 0.4500 1.5000
17a-estradiol 8.8 104 0.0120 0.0610 0.0740 0.0062
EE derivatives
EE (17a-ethinyl-E2) i 11.1 92 1.8600 0.7780 1.2090 1.3333
11-methylene-EE f i 11.2 83 1.7469 0.6490 1.8400 1.0000
11b-methyl-EE e i 11.2 85 2.0771 0.7100 1.7860 1.3300
11b-ethyl-EE h i 11.2 87 1.7783 0.5470 1.8010 2.0000
11b-ethinyl-EE i i 11.0 90 1.4567 0.4980 0.9080 nd
11b-chloromethyl-EE u i 11.0 75 1.2584 0.3950 0.9450 1.3300
Mestranol (3-methoxy-EE) r i 8.5 76 0.0045 nd nd 0.2000
17a-iodovinyl-E2 (E) v 9.9 126 0.1202 0.0010 0.4700 nd
Non-aromatic estradiol
3b-OH-11-methylene-NET f i 9.5 111 0.0449 0.0230 0.1660 nd
3b-OH-11b-ethenyl-NET k i 10.3 93 0.1820 0.0880 0.3450 0.1250
3b-OH-11b-ethyl-NET h i 9.5 79 0.0399 0.1130 0.6200 0.5000
3b-OH-7a-methyl-NET e i 10.3 85 0.2532 0.1920 0.3080 0.0080
3b-OH-5a-hydrogen-NET b i 9.2 119 0.0155 0.0250 0.0780 0.0003
3b-OH-5a-hydrogen-11-
methylene-NET
b f i 9.2 129 0.0240 0.0620 0.1550 nd
3b-OH-5a-hydrogen-11b-methyl-
NET
b e i 7.7 101 0.0626 0.0500 0.2330 0.0330
3b-OH-5a-hydrogen-11b-ethenyl-
NET
b k i 10.1 104 0.1175 0.1650 0.4900 0.0625
3b-OH-5a-hydrogen-11b-ethyl-
NET
b h i 9.5 91 0.0350 0.1130 1.4200 0.2500
3b-OH-5a-hydrogen-7a-methyl-
NET
b e i 9.7 101 0.0598 0.0690 0.2070 0.0023
3a-OH-11-methylene-NET s f i 8.2 110 0.0024 0.0050 0.0070 nd
3a-OH-11b-ethyl-NET s h i 9.0 79 0.0133 0.0370 0.0395 0.0210
3a-OH-11b-ethinyl-NET s b i i 9.3 95 0.0284 0.0750 0.0480 nd
3a-OH-7a-methyl-NET s e i 8.8 83 0.0076 0.0310 0.0530 0.0010
3a-OH-5a-hydrogen-11b-ethyl-
NET
s b h i 8.9 97 0.0103 0.0310 0.1190 0.0830
3a-OH-5b-hydrogen-7a-methyl-
NET
s b" e i 7.8 105 0.0010 0.0010 0.0030 nd
Estrogenic compounds
DES 10.4 98 0.2138 0.4670 1.7400 0.5000
Genistein 7.3 135 0.0002 0.0010 0.0030 0.0005
Antiestrogens
Tamoxifen (citrate) >5.0 <5 0.0000 0.0033 0.0010 0.0013
Clomiphene citrate 8.5 31 0.0050 0.0010 0.1920 0.0010
Nafoxidine >5.0 5 0.0000 nd nd >0.0005
ICI 164.384 >5.0 <5 0.0000 0.0010 0.0370 0.0001
Raloxifen >6.0 5 0.0000 0.0010 0.2500 0.0001
3-keto-steroids
NE t d i 9.1 99 0.0179 0.0030 0.0060 0.0020
Testosterone t >5.0 12 0.0000 0.0010 nd 0.0001
5a-hydrogen-T (DHT) t b >6.0 <5 0.0000 0.0010 0.0010 >0.0005
19-nor-T (Nandrolone) t 6.7 94 0.0001 0.0010 nd >0.0005
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the latter in vivo assay. Besides the exclusion of compounds
with RAAs below the cutoff values, compounds for which no
exact RAAwas determined (indicated as< or> in Tables 1 and 2)
were also excluded from the correlation.
The correlation of AR CALUX data with those of the
Hershberger assay was lower than found with the other AR
in vitro assays (Fig. 4A); comparison of 34 compounds resulted
in a correlation coefficient of r2 ¼ 0.46 ( p < 0.0001). Some
notable exceptions were found that showed relatively high
in vitro reporter gene activity coupled to low in vivo potential:
nandrolone (63), 11-keto-19-nor-T (73), (14b,17a,20S)-20-
OH-19-norpregna-4,9-diene-3-one (83); and 7a-methyl-17a-
(2-propenyl)-estr-5(10)-en-17b-ol (83). Also, exceptions were
found that showed relatively high in vivo activity coupled to
low in vitro reporter gene potential, for example, testosterone
(seven times difference).
The correlation of ERa CALUX data with those of Allen-
Doisy assay testing 31 compounds was excellent (r2 ¼ 0.87;
p < 0.0001) (Fig. 4B). In this in vitro/in vivo comparison,
exceptions were found that showed relatively high in vitro
reporter gene activity and low in vivo potential: 3b-OH-7a-
methyl-NET (323), 3b-OH-5a-hydrogen-7a-methyl-NET
(263), and 3b-OH-5a-hydrogen-NET (523). Again, excep-
tions were found that showed relatively high in vivo activity
coupled to low in vitro reporter gene activity: 3b-OH-11b-
ethyl-NET (12 times difference) and mestranol (443). In
addition, comparable correlations were found using CHO-
derived reporter gene data and Hershberger and Allen-Doisy
data for both AR (r2¼ 0.47; n¼ 31; p < 0.0001) and ERa (r2¼
0.78; n ¼ 32; p < 0.0001) (data not shown).
Compound Activity Profiling Using Multiple Assays
The large steroid compound data set obtained with various
in vitro and in vivo assays (see Tables 1 and 2) allows the cross-
assay bioactivity profiling of a given compound. By means of
hierarchical clustering, bioactivity relationships between both
compounds and between various bioassays can be determined.
Furthermore, these relationships can be visualized easily by
coloring the activity of a compound; the higher the activity of
the compound in a certain assay, the more intense the red color
(see Fig. 5). Since our interest was in the evaluation of in vitro
assays as prescreen for in vivo screens, we concentrated on the
trends rather than on the absolute numbers. For this reason, the
hierarchical clustering was performed on the base 10 logarithm
of the RAA data.
TABLE 2—Continued
Compound
Modification ERa CALUX
CHO-ERa ER binding Allen-Doisy
R3 R4–5 R6 R7 R11 R17 LogEC50 (M) RTA (%) RAA 1 ¼ E2 RAA 1 ¼ E2 RBA 1 ¼ E2 RAA 1 ¼ E2
5a-hydrogen-19-nor-T t b 6.5 125 0.0001 0.0010 nd nd
11b-methyl-19-nor-T t e 6.5 98 0.0001 0.0010 nd nd
11-keto-19-nor-T t n >5.0 <5 0.0000 0.0010 nd nd
R1881 t 6.2 61 0.0000 0.0010 nd nd
Progestagens
Progesterone t >6.0 <5 0.0000 <0.0002 0.0060 nd
17a-Progesterone t w >5.0 <5 0.0000 0.0010 0.0010 nd
NET t i 6.7 88 0.0001 0.0010 0.0030 0.0001
MPA t e >6.0 <5 0.0000 0.0010 nd nd
CA t >6.0 <5 0.0000 0.0010 nd nd
LNG t i 5.8 92 0.0000 0.0010 0.0020 0.0001
Norgestimate t >5.0 <5 0.0000 0.0010 nd nd
Cronolon t 6.2 54 0.0000 0.0010 0.0010 nd
6a-methyl-19-nor-T t e 5.3 94 0.0000 0.0010 nd nd
7a-methyl-19-nor-T (MENT) t e 7.6 96 0.0007 0.0014 nd 0.0004
6a-methyl-NET t e i >5.0 16 0.0000 0.0010 nd nd
7a-methyl-NET t e i 7.4 107 0.0004 0.0010 0.0010 0.0020
5a-hydrogen-11b-methyl-NET t b e i 7.9 117 0.0013 0.0067 0.0048 nd
5a-hydrogen-NET t b i 7.9 101 0.0012 0.0043 0.0020 0.0003
Antiprogestagen
RU 486 (Mifepristone) t 5.9 31 0.0000 0.0010 0.0010 nd
Glucocorticoid
Dexamethasone t >5.0 <5 0.0000 0.0010 0.0010 >0.0005
Note. LogEC50 values, Relative Transcriptional Activity (RTA), and Relative Agonistic Activity (RAA) of various compounds in the ERa CALUX reporter
gene assay, and their corresponding RAA and Relative Binding Activity (RBA) in the CHO-ERa reporter gene assay, ER binding assay, and Allen-Doisy assay.
nd ¼ not determined. Abbreviations: b ¼ 5a-hydrogen; b$ ¼ 5b-hydrogen; d ¼ D5–10; e ¼ methyl; f ¼methylene; h ¼ ethyl; i ¼ ethinyl; k ¼ ethenyl; n ¼ keto;
r ¼ 3-methoxy; s ¼ 3a-hydroxy; t ¼ 3-keto; u ¼ chloromethyl; v ¼ 17a-iodovinyl; w ¼ 17a-hydroxy; R3 ¼ 3-position; R4–5 ¼ 4–5-position; R6 ¼ 6a-position;
R7 ¼ 7a-position; R11 ¼ 11-position; R17 ¼ 17-position.
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Although the dataset of androgenic or estrogenic compounds
tested in all four assays is rather limited (only those compounds
included that in all correlations were used; n ¼ 26 for the
androgens and n ¼ 30 for the estrogens), already interesting
relationships in both directions (compounds and assays) could
be observed (Fig. 5). For the androgenic compounds, the
compounds with 11b-substitutions, 5a-hydrogen, or 7a-methyl
substitutions tend to cluster separately (Fig. 5A). For the
estrogenic compounds, the structure relationships are more
evident; the groups of E2-derivatives, EE-derivatives, and
NET-derivatives with 3b-OH/5a-hydrogen substitutions
clearly cluster separately (Fig. 5B). Besides these compound
relationships, relationships between the different assays can
also be determined. For the dataset used, the AR CALUX
FIG. 2. Comparison of different in vitro reporter gene assays for de-
termination of androgenic and estrogenic activity of various compounds.
Relative Agonistic Activities (RAAs) of various androgenic or estrogenic
compounds (see Tables 1 and 2) were determined by AR and ERa CALUX
reporter gene assays and compared with their corresponding RAAs obtained
with CHO-AR (A) and CHO-ERa (B) reporter gene assays, respectively.
FIG. 3. Comparison of in vitro CALUX reporter gene assays with in vitro
receptor binding assays for determination of androgenic and estrogenic activity
of various compounds. Relative Agonistic Activities (RAAs) of various
androgenic or estrogenic compounds (see Tables 1 and 2) were determined
by AR and ERa CALUX reporter gene assays and compared with the relative
binding activities (RBAs) obtained with AR (A) and ER (B) receptor binding
assays, respectively.
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reporter gene assay is most related to the AR binding assay and
the in vivo Hershberger assay clusters separately from the other
in vitro assays (Fig. 5A). For the estrogenic compound dataset,
different assay relationships are observed. Here, the ERa
CALUX reporter gene assay is most related to the in vivo
Allen-Doisy assay, while the ER binding assay clusters
separately from the other assays (Fig. 5B). Furthermore, it is
obvious that the similarity between the different estrogen
reporter assays is higher than for the androgen reporter assays,
indicated by the small distance between the individual estrogen
assays and the larger distance between the Hershberger assay
and the other androgen assays (Fig. 5).
DISCUSSION
To get insight in the robustness of the in vitro data set, we
have made an extensive comparison between assays used to
determine androgenicity and estrogenicity. Excellent correla-
tions were found between different reporter gene assays, and
these results were also very comparable with the data of the
receptor binding assays. These results are remarkable, since we
used different reporter gene assays at different locations, and
different experimental protocols. This demonstrates the ro-
bustness of the currently used reporter gene assays when
carried out in experienced laboratories. The intra-laboratory
CVs that we calculated for the different reporter gene assays of
12–25% compare well with previously published data of other
laboratories (Andersen et al., 1999; Ko¨rner et al., 2004).
An illustration is provided how to handle a large steroid
compound data set obtained with various bioassays allowing
the cross-assay bioactivity profiling of a given compound. By
using a hierarchical clustering algorithm, activity relationships
between compounds and also relationships between various
bioassays (as discussed previously) can be determined. In this
study the dataset of androgenic or estrogenic compounds is
rather limited, but already interesting relationships in both
directions (compounds and assays) were observed. This way of
data handling proves promising for building a compound
activity database which can be used to profile the activity of
new (pharmaceutical) compounds and even to determine the
identity of unknown compounds present in various matrices,
such as blood/urine (clinical and sport doping applications),
food/feed, and environmental samples. The success of the latter
option depends greatly on the number of compounds and
assays within the database.
Comparison of the data of the reporter gene assays with
receptor binding assays again revealed a good correlation,
confirming that nuclear receptor binding is a critical step in
steroid action. The receptors used in all of our assays are of
human origin, explaining the high levels of concordance
between the data. The fact that we used reporter gene assays
in which the receptors were stably introduced under control of
a constitutive promoter has likely contributed to the robustness
of the response. Expectedly, antagonists scored negative in
reporter gene assays while being positive in receptor binding
assays. The characteristic of binding agonists as well as
antagonists is a clear drawback of binding assays, since many
compounds have been found that can act antagonistically
toward the androgen and estrogen receptor. For example, it
has been found that a wide variety of environmental chemicals
FIG. 4. Comparison of in vitro CALUX reporter gene assays with the
in vivo Hershberger and Allen-Doisy assays for determination of androgenic
and estrogenic activity of various compounds. Relative Agonistic Activities
(RAAs) of various androgenic or estrogenic compounds (see Tables 1 and 2)
were determined by AR and ERa CALUX reporter gene assays and compared
with the RAAs obtained with the Hershberger androgenic assay (A) and the
Allen-Doisy estrogenic assay (B), respectively.
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FIG. 5. Hierarchical clustering of androgenic and estrogenic compounds. Relative Agonistic Activities (RAAs) of androgenic or estrogenic compounds (see
Tables 1 and 2) determined by all used assays were clustered according to the hierarchical clustering method. (A) Androgenic compounds (n¼ 26) in relation to the
androgenic assays (AR CALUX and CHO-AR reporter gene assays, AR binding and Hershberger assay). (B) Estrogenic compounds (n ¼ 30) in relation to the
estrogenic assays (ERa CALUX and CHO-ERa reporter gene assays, ER binding and Allen-Doisy assay). The intenser the red color, the higher the activity of
the compound. Black means no activity.
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have weak anti-androgenic activity (Schreurs et al., 2005;
Sonneveld et al., 2005). In the reporter gene assays used,
antagonistic activity can easily be dissected from agonistic
activity by changing the experimental setting (Schoonen et al.,
2000a; Sonneveld et al., 2005).
Although the correlation between the results of the different
in vitro assays was very strong, expectedly the correlation with
the in vivo data was weaker, as is generally experienced when
trying to mimic the complex physiology in whole animals using
in vitro systems. Although the in vitro data showed a very good
correlation with the Allen-Doisy test, which measures vaginal
cornification in ovariectomized rats (this study; de Gooyer et al.,
2003; Schoonen et al., 2000a), as was also demonstrated earlier
by Yamasaki et al. (2002) for a HeLa cell line derived ERa
reporter gene cell line and the rat uterotrophic assay, the
correlation with the Hershberger test was weaker (this study;
Schoonen et al., 2000a,b). This mainly seems to be related to the
difference in sensitivity between both in vivo assays. While the
physiological dose for an active estrogen ranges from 10 to
100 pM, the physiological dose for an active androgen ranges
from 0.2 to 10 nM. This means that for the Allen-Doisy assay
a much lower amount of estrogenic compound can be applied to
the animal to activate the estrogen receptor (e.g., 0.5 lg/kg of
17b-estradiol) than for androgens activating the AR in the
Hershberger assay (160 lg/kg of testosterone), For the weaker
androgens, the activating dose might even not be reached.
It should be noted that in this study we have restricted ourselves
to measuring relatively potent activities of compounds with
a pharmacological interest, using relatively low maximal doses
of compounds. This might imply that, in other fields such as
chemical risk analysis of chemicals, using relatively weaker
compounds, the Hershberger assay might not be very suitable
as a test system (Charles et al., 2005), while in vivo estrogen
assays are, as shown recently for bisphenol A and closely related
compounds (Kitamura et al., 2005).
In our hands, in both assays the response of individual
compounds in vitro was almost without exception able to
predict the in vivo activity with an uncertainty of a factor 10 or
less in either direction, suggesting that, overall, the correlation
between the two types of in vivo tests with their corresponding
in vitro tests will not be very different when expanding the
dataset. This ability to predict the in vivo activity of chemicals
within a factor 10 difference seems satisfactory for a number of
applications. An important requirement in activity screens,
particularly when related to risk analysis is a low level of false-
negative predictions. Because of the high sensitivity of the
in vitro screens, these false-negatives can easily be avoided
even when taking an uncertainty factor of 10–100 into account.
There may be various reasons for the differences between the
in vitro and in vivo data. First of all, since the nuclear receptors
are the most important determinants of steroid action, varia-
tions in binding characteristics will change the outcome of an
assay. Since there are species differences between the receptors
used in different assays, being human derived in the in vitro
assays and rodent in the in vivo assays, this might have
contributed to differences in responses. However, it is unlikely
that these species differences contribute to a large extent to the
differences between in vitro and in vivo data, since the steroid
receptors and their binding characteristics are very well
conserved between species, and certainly between mammals
(Escriva et al., 2004; Owen and Zelent, 2000). However, the
presence/absence of specific cofactors (coactivators and cor-
epressors) for the receptors may account for subtle differences
between the results of the different assays in a way that is
difficult to predict. A major source of differences may be the
differences in metabolism and pharmacokinetics, involving
adsorption, distribution (including binding to general and
steroid-specific binding proteins), and excretion of steroids in
the different assay systems. All these latter mechanisms will
generally be underrepresented in an in vitro system. Since our
test compounds were mainly steroidal, specific metabolic
conversions could have occurred that have the potential to
greatly influence their hormonal activity. Steroid hormones
undergo active metabolism through specific enzymatic con-
versions such as activating CYP17, CYP19, 3a, 3b-, and 17b-
HSD, and 5a-reductase activities (Auchus, 2004; Soronen
et al., 2004) and inactivating glucuronidase and sulfatase
activities (Basinska and Florianczyk, 2003), leading to com-
pounds with altered biological activity. In fact, there are
many indications that metabolism is an important source of
differences between the in vitro and in vivo assays, as is
illustrated below.
The activity of DHT was equal to that of testosterone in vivo,
in contrast to in vitro, where DHT was the more active
compound. The latter observation is commonly accepted for
in vitro AR reporter gene assays (de Gooyer et al., 2003;
Sonneveld et al., 2005; Wilson et al., 2002). An explanation for
the observation that testosterone seems to be favored in the
Hershberger assay can be that the metabolic clearance in vivo is
faster for DHT (Kumar et al., 1999), due to 3a and 3b-
hydroxylation, glucuronidation, and sulfation, besides only
17b-HSD activity acting on testosterone, resulting in testoster-
one as the abundant androgen in serum and net similar results
for testosterone and DHT in the Hershberger assay. Addition-
ally, in vitro 5a-reductase activities in U2-OS and CHO cells
might be low compared to the in vivo situation. Surprisingly,
propionate modifications at R17 are much less potent in CHO
cells compared to testosterone. In U2-OS cells and in vivo this
clearly was not the case, suggesting a relatively low esterase
activity in CHO cells. This suggestion is strengthened by the
fact that EE and its derivatives are also more potent in U2-OS
and the in vivo Allen-Doisy compared to CHO cells.
Specific structure/activity relationships were noted for
androgens as well as estrogens from modifications on various
positions within the androgen or estrogen molecule included in
this study (see Tables 1 and 2). Some of the modifications
clearly influenced the relative potency in vitro and in vivo of
the compounds. For example, comparing testosterone with its
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19-nor derivatives nandrolone (19-nor-testosterone), 11b-
methyl-19-nor-testosterone, and 11-methylene-19-nor-testos-
terone, the 19-nor compounds are 3 to 12 times more potent
than testosterone in in vitro binding and reporter gene assays,
but around 15-fold weaker than testosterone in the in vivo
Hershberger assay. This in vivo difference might be due to the
fact that, in the accessory sex organs (e.g., the prostate),
testosterone is 5 alpha-reduced to DHT, which, due to its higher
affinity for AR, amplifies the action of testosterone. In contrast,
when 19-nor-testosterone is 5 alpha-reduced its affinity for AR
decreases, resulting in a decrease in its androgenic potency
(Kumar et al., 1999; Sundaram et al., 1995). Addition of a large
substituent to 19-nor-testosterone at the 17a-position, like an
ethinyl (norethisterone: NET) or propenyl (17a-(2-propenyl)-
19-nor-testosterone), sharply reduces the androgenic activity
in vitro, while the in vivo activities of these compounds remain
the same as for nandrolone. This latter might be due to the
higher in vivo stability of these compounds, as is the case for
17a-ethinyl-E2 in comparison to E2 in the ER bioassays
(Fotherby, 1996). On the other hand, a small methyl addition
to the 6a-, 7a-, 11-, 11b-, or 17a-position is allowed without
a tremendous reduction in potency in vitro and in vivo, with the
exception of the 7a-methyl addition (MENT) resulting in an
increase in in vitro (4-fold compared to nandrolone) and in vivo
(16-fold compared to nandrolone) activities. The high potency
of MENT is primarily related to its higher affinity to AR as was
proposed earlier by Kumar et al. (1999) and shown by AR
binding in this study. As expected for hydroxylated steroids,
a polar group like 11a-OH or 11b-OH reduces the activity by at
least 50-fold for 19-nor-testosterone derivatives, in vitro as well
as in vivo.
In U2-OS cells 17b-HSD activity is also present, suggested
by the activity of the testosterone precursor androstenedione in
the AR CALUX reporter gene assay (this study) and RT-PCR
experiments (data not shown), while binding to the AR is
relatively low. Unfortunately, no CHO and Hershberger data
are present for this compound.
Another notable exception was progesterone being negative
in vitro, but active in the Hershberger assay. Progesterone is
generally not considered to have strong androgenic activity, but
in the Hershberger assay possibly is converted to active
androstenedione/testosterone. In addition, MPA and LNG-
(acetate) were also positive androgenic in vivo progestagenic
compounds, suggesting that other progestagenic compounds
are also active in the Hershberger assay (as demonstrated by
Schoonen et al., 2000a,b). Other hormones that were suggested
to be possibly active in the Hershberger assay are estrogens.
Clearly, ERb is highly expressed in the prostate, and inhibition
of ventral prostate proliferation is regulated by ERb ligands,
while loss of ERb is associated with tumor progression (Bardin
et al., 2004; Imamov et al., 2004). The fact that other hormones
than androgens have effects in the Hershberger assay indicate
that the in vivo assays are never entirely specific (Zacharewski,
1998).
Metabolic activities, combined with nonselectivity of the
in vivo assays may lead to surprising results. For example 3-
hydroxy substitution of androgens (due to 3a- and 3b-HSD
activity) leads to inactive androgens, while estrogenic com-
pounds can be converted to progestagens, especially in case of
the NET derivatives. For progestagens, it is known that they
can inhibit the estrogenic activity in the Allen-Doisy test
(Schoonen et al., 2000b). Thus if a compound is metabolized
into active progestagens, only measurement in the presence of
an anti-progestagen allows the correct in vivo determination of
the estrogenic activity. Within Organon, examples for 11b-
ethyl-NET and 11b-ethenyl-NET are available, in which these
compounds are much more potent in an Allen-Doisy test in
combination with an anti-progestagen than when given alone
(data not shown). Taken together, the observed results suggest
that metabolism, combined with relative nonspecificity of the
in vivo assays can lead to differences between in vitro and
in vivo assays.
Our results suggest that inclusion of ADME could further
improve the predictions made by the in vitro models. It should
be noted, however, that these predictions can never be
absolutely exact. This situation is not different in the in vivo
models where species and strain differences have been re-
ported in the response to hormonal agents that can reach two to
three orders of magnitude (Hengstler et al., 1999; Spearow
et al., 1999, 2001). Even within an organism, the response of
different target organs to hormones may vary strongly, which
has been shown elegantly using transgenic mice expressing
reporter gene constructs (Ciana et al., 2003; Lemmen et al.,
2004). In this light the in vitro predictions, deviating a factor 10
from the in vivo data are remarkably accurate, especially
because different species are used in the models. In vitro
models have a clear advantage of being able to use human
materials either directly applied on the reporter cells (e.g.,
plasma or serum; Sonneveld et al., 2005) or extracted (e.g.,
urine; Legler et al., 2002). This, however, also poses a problem
when validating such models. When trying to further improve
the in vitro models, one of the difficulties will be the absence
of sufficient appropriate in vivo determinations, since these
ideally are human clinical data.
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